TY - JOUR
T1 - Polygenic Risk Scores in Clinical Psychology
T2 - Bridging Genomic Risk to Individual Differences
AU - Bogdan, Ryan
AU - Baranger, David A.A.
AU - Agrawal, Arpana
N1 - Funding Information:
R.B. was supported by the US National Institute on Aging (grant R01-AG045231), the National Institute of Child Health and Human Development (grant R01-HD083614), and the National Institutes of Health (grant U01-AG052564). D.A.A.B. was funded by the National Science Foundation (grant DGE-1745038). A.A. was funded by the National Institute on Drug Abuse (grant K02DA32573)
Funding Information:
R.B. was supported by the US National Institute on Aging (grant R01-AG045231), the National Institute of Child Health and Human Development (grant R01-HD083614), and the National Institutes of Health (grant U01-AG052564). D.A.A.B. was funded by the National Science Foundation (grant DGE-1745038). A.A. was funded by the National Institute on Drug Abuse (grant K02DA32573).
Publisher Copyright:
© Copyright 2018 by Annual Reviews. All rights reserved.
PY - 2018/5/7
Y1 - 2018/5/7
N2 - Genomewide association studies (GWASs) across psychiatric phenotypes have shown that common genetic variants generally confer risk with small effect sizes (odds ratio < 1.1) that additively contribute to polygenic risk. Summary statistics derived from large discovery GWASs can be used to generate polygenic risk scores (PRS) in independent, target data sets to examine correlates of polygenic disorder liability (e.g., does genetic liability to schizophrenia predict cognition?). The intuitive appeal and generalizability of PRS have led to their widespread use and new insights into mechanisms of polygenic liability. However, when currently applied across traits they account for small amounts of variance (<3%), are relatively uninformative for clinical treatment, and, in isolation, provide no insight into molecular mechanisms. Larger GWASs are needed to increase the precision of PRS, and novel approaches integrating various data sources (e.g., multitrait analysis of GWASs) may improve the utility of current PRS.
AB - Genomewide association studies (GWASs) across psychiatric phenotypes have shown that common genetic variants generally confer risk with small effect sizes (odds ratio < 1.1) that additively contribute to polygenic risk. Summary statistics derived from large discovery GWASs can be used to generate polygenic risk scores (PRS) in independent, target data sets to examine correlates of polygenic disorder liability (e.g., does genetic liability to schizophrenia predict cognition?). The intuitive appeal and generalizability of PRS have led to their widespread use and new insights into mechanisms of polygenic liability. However, when currently applied across traits they account for small amounts of variance (<3%), are relatively uninformative for clinical treatment, and, in isolation, provide no insight into molecular mechanisms. Larger GWASs are needed to increase the precision of PRS, and novel approaches integrating various data sources (e.g., multitrait analysis of GWASs) may improve the utility of current PRS.
KW - Candidate
KW - GWAS
KW - PRS
KW - Polygenic
KW - Psychopathology
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85042518900&partnerID=8YFLogxK
U2 - 10.1146/annurev-clinpsy-050817-084847
DO - 10.1146/annurev-clinpsy-050817-084847
M3 - Article
C2 - 29579395
AN - SCOPUS:85042518900
SN - 1548-5943
VL - 14
SP - 119
EP - 157
JO - Annual Review of Clinical Psychology
JF - Annual Review of Clinical Psychology
ER -